Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, Scotland G4 0RE, UK.
Precision NanoSystems Inc, #50 655 W Kent Ave N, Vancouver, BC V6P 6T7, Canada.
Int J Pharm. 2020 May 30;582:119266. doi: 10.1016/j.ijpharm.2020.119266. Epub 2020 Apr 3.
Nanomedicines are well recognised for their ability to improve therapeutic outcomes. Yet, due to their complexity, nanomedicines are challenging and costly to produce using traditional manufacturing methods. For nanomedicines to be widely exploited, new manufacturing technologies must be adopted to reduce development costs and provide a consistent product. Within this study, we investigate microfluidic manufacture of nanomedicines. Using protein-loaded liposomes as a case study, we manufacture liposomes with tightly defined physico-chemical attributes (size, PDI, protein loading and release) from small-scale (1 mL) through to GMP volume production (200 mL/min). To achieve this, we investigate two different laminar flow microfluidic cartridge designs (based on a staggered herringbone design and a novel toroidal mixer design); for the first time we demonstrate the use of a new microfluidic cartridge design which delivers seamless scale-up production from bench-scale (12 mL/min) through GMP production requirements of over 20 L/h using the same standardised normal operating parameters. We also outline the application of tangential flow filtration for down-stream processing and high product yield. This work confirms that defined liposome products can be manufactured rapidly and reproducibly using a scale-independent production process, thereby de-risking the journey from bench to approved product.
纳米药物因其能够改善治疗效果而广为人知。然而,由于其复杂性,使用传统制造方法来生产纳米药物具有挑战性且成本高昂。为了广泛利用纳米药物,必须采用新的制造技术来降低开发成本并提供一致的产品。在本研究中,我们研究了纳米药物的微流控制造。使用载有蛋白质的脂质体作为案例研究,我们从小规模(1 毫升)到 GMP 规模生产(200 毫升/分钟)制造具有严格定义的物理化学特性(大小、PDI、蛋白质负载和释放)的脂质体。为此,我们研究了两种不同的层流微流控盒设计(基于交错人字形设计和新型环形混合器设计);我们首次展示了使用新的微流控盒设计,该设计使用相同的标准化正常运行参数,从台式机(12 毫升/分钟)无缝扩展到超过 20 L/h 的 GMP 生产要求。我们还概述了切向流过滤在下游处理和高产物收率方面的应用。这项工作证实,使用与规模无关的生产工艺可以快速且可重复地制造出定义明确的脂质体产品,从而降低了从实验室到批准产品的风险。